Pretreatment Characteristics of 182 Patients With Ann Arbor Stage II-IV High-Grade Malignant B-Cell Lymphomas of the Kiel Classification1,2 Treated by the COP-BLAM/IMVP-16 Regimen5
| . | Lymphoma Subtype . | P* . | ||
|---|---|---|---|---|
| . | CB n (%) . | B-IB n (%) . | B-ALC n (%) . | . |
| Total n | 127 (70) | 33 (18) | 22 (12) | |
| Gender, male:female | 72:55 | 24:9 | 11:11 | .09 |
| Age, median (range) yrs | 56 (16-75) | 59 (20-73) | 61 (25-74) | n.s. |
| International index | ||||
| Age > 60 yrs | 42/127 (33) | 13/33 (39) | 11/22 (50) | n.s. |
| Karnofsky index ≤ 70% | 28/125 (22) | 13/33 (39) | 7/21 (33) | n.s. |
| Serum-LDH > normal | 64/127 (50) | 21/31 (68) | 15/22 (68) | .10 |
| Ann Arbor stage III/IV | 90/127 (71) | 25/33 (76) | 12/22 (55) | n.s. |
| No. of E-sites† ≥ 2 | 23/127 (18) | 10/33 (30) | 5/22 (23) | n.s. |
| Risk group‡ L (0, 1) | 47/125 (38) | 6/31 (19) | 6/21 (28) | n.s. |
| L-I (2) | 34/125 (27) | 8/31 (26) | 5/21 (24) | n.s. |
| H-I (3) | 33/125 (26) | 12/31 (39) | 6/21 (29) | n.s. |
| H (4, 5) | 11/125 (9) | 5/31 (16) | 4/21 (19) | n.s. |
| B-Symptoms | 69/164 (54) | 15/33 (45) | 11/22 (50) | n.s. |
| Manifestation pattern | ||||
| Largest lymphoma ≥ 10 cm | 11/107 (10) | 9/28 (32) | 4/20 (20) | .06 |
| Presence of E-site1 | 85/127 (67) | 19/33 (58) | 9/22 (41) | n.s. |
| Gastrointestinal site | 28/127 (22) | 8/33 (24) | 3/22 (14) | n.s. |
| Liver and/or spleen | 36/127 (28) | 13/33 (39) | 8/22 (36) | n.s. |
| Skin and/or bone | 14/127 (11) | 7/33 (21) | 4/22 (18) | n.s. |
| Bone marrow positive | 17/127 (13) | 3/33 (9) | 1/22 (5) | n.s. |
| . | Lymphoma Subtype . | P* . | ||
|---|---|---|---|---|
| . | CB n (%) . | B-IB n (%) . | B-ALC n (%) . | . |
| Total n | 127 (70) | 33 (18) | 22 (12) | |
| Gender, male:female | 72:55 | 24:9 | 11:11 | .09 |
| Age, median (range) yrs | 56 (16-75) | 59 (20-73) | 61 (25-74) | n.s. |
| International index | ||||
| Age > 60 yrs | 42/127 (33) | 13/33 (39) | 11/22 (50) | n.s. |
| Karnofsky index ≤ 70% | 28/125 (22) | 13/33 (39) | 7/21 (33) | n.s. |
| Serum-LDH > normal | 64/127 (50) | 21/31 (68) | 15/22 (68) | .10 |
| Ann Arbor stage III/IV | 90/127 (71) | 25/33 (76) | 12/22 (55) | n.s. |
| No. of E-sites† ≥ 2 | 23/127 (18) | 10/33 (30) | 5/22 (23) | n.s. |
| Risk group‡ L (0, 1) | 47/125 (38) | 6/31 (19) | 6/21 (28) | n.s. |
| L-I (2) | 34/125 (27) | 8/31 (26) | 5/21 (24) | n.s. |
| H-I (3) | 33/125 (26) | 12/31 (39) | 6/21 (29) | n.s. |
| H (4, 5) | 11/125 (9) | 5/31 (16) | 4/21 (19) | n.s. |
| B-Symptoms | 69/164 (54) | 15/33 (45) | 11/22 (50) | n.s. |
| Manifestation pattern | ||||
| Largest lymphoma ≥ 10 cm | 11/107 (10) | 9/28 (32) | 4/20 (20) | .06 |
| Presence of E-site1 | 85/127 (67) | 19/33 (58) | 9/22 (41) | n.s. |
| Gastrointestinal site | 28/127 (22) | 8/33 (24) | 3/22 (14) | n.s. |
| Liver and/or spleen | 36/127 (28) | 13/33 (39) | 8/22 (36) | n.s. |
| Skin and/or bone | 14/127 (11) | 7/33 (21) | 4/22 (18) | n.s. |
| Bone marrow positive | 17/127 (13) | 3/33 (9) | 1/22 (5) | n.s. |